AC Immune earnings missed, revenue fell short of estimates
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump vows to “bomb the hell out of the shoreline” to reopen Hormuz Goldman warns S&P 500 could decline to 6300 if growth weakens Morgan Stanley says Fed risks are skewed towards later and more cuts AI winners and losers: This sector is seen as ’a clear beneficiary’ 🧠 Upgrade to AI Insights (South Africa Philippines Nigeria) 🧠 Upgrade to AI Insights AC Immune earnings missed, revenue fell short of estimates By Earnings Published 03/14/2026, 04:20 PM AC Immune earnings missed, revenue fell short of estimates 0 ACIU 0.50% Investing.com - AC Immune (NASDAQ: ACIU ) reported first quarter EPS of CHF-0.164, worse than the analyst estimate of CHF-0.157. Revenue for the quarter came in at CHF891.46K versus the consensus estimate of CHF1.24M. AC Immune’s stock price closed at CHF3.02. It is down -8.360% in the last 3 months and up 31.660% in the last 12 months. AC Immune saw positive EPS revisions and negative EPS revisions in the last 90 days. See AC Immune’s stock price’s past reactions to earnings here . According to InvestingPro , AC Immune’s Financial Health score is " fair performance ". Check out AC Immune’s recent earnings performance , and AC Immune’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Read full article at source